Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules pe...

FDA Recall #D-145-2013 — Class II — December 18, 2012

Recall #D-145-2013 Date: December 18, 2012 Classification: Class II Status: Terminated

Product Description

Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.

Reason for Recall

Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).

Recalling Firm

Watson Pharmaceuticals — Parsippany, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

3,040 bottles

Distribution

Nationwide and Puerto Rico

Code Information

Lot #: 512146A, Exp 01/31/2014

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated